Will Rubin
About Will Rubin
Will Rubin is the Director of Key Customer Marketing & Pipeline at Nektar Therapeutics, where he has worked since 2020. He has extensive experience in marketing and research, holding a Ph.D. in Neurobiology from Duke University and previously working at Genentech and WWMR, Inc.
Current Role at Nektar Therapeutics
Will Rubin has been serving as the Director of Key Customer Marketing & Pipeline at Nektar Therapeutics since 2020. In this role, he is responsible for creating unbranded pathway education campaigns and overseeing pre-launch Key Opinion Leader (KOL) strategy and engagement. His work focuses on preparing for the commercialization of novel immuno-oncology new molecular entities (NMEs) and managing early-stage new molecular entities in infectious diseases. He operates from the San Francisco Bay Area.
Professional Experience
Prior to his current position, Will Rubin held various roles in the pharmaceutical and biotechnology sectors. He worked at Genentech as a Marketing Principal from 2010 to 2020, where he contributed to marketing strategies and product development. He also served as a Market Research Analyst and Consultant at WWMR, Inc. from 2006 to 2009. Additionally, he was a Postdoctoral Scientist in Neurobiology at the University of California, Davis from 2002 to 2006.
Education and Expertise
Will Rubin earned a Ph.D. in Neurobiology from Duke University, where he focused on advanced studies in the field. He also holds a Bachelor of Arts degree from Northwestern University, where he studied in the Integrated Science Program. His educational background equips him with a strong foundation in both scientific research and marketing within the biotechnology industry.
Key Contributions
In his role at Nektar Therapeutics, Will Rubin has been instrumental in developing strategies for early-stage new molecular entities and leading initiatives for KOL engagement. His efforts in creating unbranded pathway education campaigns demonstrate his commitment to enhancing understanding and accessibility of new treatments in the market. His experience spans over a decade in various capacities, contributing to significant advancements in the pharmaceutical sector.